Showing 6811-6820 of 7640 results for "".
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,
- Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketinghttps://practicaldermatology.com/news/aesthetics-industry-veteran-pat-altavilla-joins-suneva-medical-as-vice-president-of-marketing/2458410/Suneva Medical, Inc., appointed Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand's strong le
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- Meet the Newest Filler on the Block: Biologica Technologies' Allofill™https://practicaldermatology.com/news/meet-the-newest-filler-on-the-block-biologica-technologies-allofill/2458412/A newly launched off-the-shelf fat-derived filler may provide the long-lasting results associated with fat grafting plus the convenience of other ready-to-use injectables. Allofill is Biologica Technologi
- DermTech Announces Validation Study Publicationhttps://practicaldermatology.com/news/dermtech-announces-validation-study-publication/2458414/DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory diseases, recently published "Development and Validation of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma", in the Journal of the American A
- At-Home Nail Fungus Treatment Now Available From iSkinProductshttps://practicaldermatology.com/news/at-home-nail-fungus-treatment-now-available-from-iskinproducts/2458415/Cure-Ex nail fungus laser treatment device is now available from online beauty retailer, iSkinProducts. The portable device can be used on fingernails or toenails and a user can use the Cure-Ex laser from the comfort of their own home, according to the company. The Cure-Ex nail fungus tre
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac
- New From Neocutis: Meet the Micro-Riche Linehttps://practicaldermatology.com/news/new-from-neocutis-meet-the-micro-riche-line/2458420/NEOCUTIS is rolling out a new line. The MICRO-RICHE ultra-hydrating line will expand the company’s MICRO-PROTEIN Complex (MPC) product line. The new MICRO-RICHE line includes more emollient versions of MICRO-NIGHT and MICRO-EYE to keep skin nourished and hydrated as winter approache
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription